Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of first-line immunochemotherapy across KRAS mutation subtypes in advanced lung adenocarcinoma.

International journal of cancer - 15 Jun 2026

Jin Hongping, Huang Honglei, Wu Yiqing, Zhang Yidan, Xu Jianlin, Liu Tengfei, Zhong Hua, Miao Qian, Zhong Runbo

Abstract excerpt

The impact of KRAS mutation subtypes on treatment response to first-line immunochemotherapy in advanced lung adenocarcinoma (LUAD) remains uncertain. This study evaluated treatment efficacy across KRAS subtypes and examined the role of programmed death-ligand 1 (PD-L1) expression and co-mutations. We retrospectively analyzed 335 patients with advanced KRAS-mutant LUAD treated with first-line immunochemotherapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to B7-H1 Antigen

Share to Lung Neoplasms

Share to Progression-Free Survival

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 41634944
DOI: 10.1002/ijc.70362

Genes

KRAS
STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of first-line immunochemotherapy across KRAS mutation subtypes in advanced lung adenocarcinoma.PMID 41634944Read ↗

Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With ImmunotherapySemantic proximity Read ↗

KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study.Semantic proximity Read ↗

Clinicopathological Characteristics and Prognostic Impact of KRAS Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Prognostic value of KRAS G12C in advanced non-small cell lung cancer with high PD-L1 expression treated with upfront immunotherapy: a systematic review and meta-analysis.Semantic proximity Read ↗

Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.Semantic proximity Read ↗

Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.Semantic proximity Read ↗

A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.Semantic proximity Read ↗

Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy.Semantic proximity Read ↗

[Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].Semantic proximity Read ↗

KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.Semantic proximity Read ↗

Molecular and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer Harboring KRAS G12V Mutations.Semantic proximity Read ↗

KRAS-mutant advanced NSCLC: efficacy and clinical outcomes from network meta-analysis and real-world evidence.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.